EpiScreen™ Epitope Mapping Fact Sheet

Further information on Abzena’s accurate and sensitive ex vivo T cell epitope identication technology including example results.


iTope™ and TCED™ Fact Sheet

More information on Abzena’s iTope™ and TCED™ technology including a detailed look at the results.


EpiScreen™ Time Course T Cell Assay Fact Sheet

More information on the EpiScreen™ time course T cell assay and a case study showing the potential immunogenicity of A33 and trastuzumab. Download (pdf)



ImmunoTX Summit

6 February 2017

ImmunoTX Summit Read more

BIO San Diego 2017

19 June 2017

The Golden State is the home of many firsts for the life sciences sector – the first biotechnology company, the first biotechnology public offering, the first biotechnology drug approved by the FDA, the first companion diagnostic company and the first agricultural biotechnology company – just to name a few. With over 242,000 Californians directly employed […] Read more


1 May 2017

Abzena will be exhibiting and presenting at PEGS Boston, May 1st-5th in Boston, MA Read more


A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors.

Carl I. Webster, Christine J. Bryson, Edward A. Cloake, Tim D. Jones, Mark J. Austin, Anette C. Karle, Sebastian Spindeldreher, David C. Lowe & Matthew P. Baker. mAbs, Volume 8, Issue 2, 2016 ABSTRACT The immunogenicity of clinically administered antibodies has clinical implications for the patients receiving them, ranging from mild consequences, such as increased clearance of […] Read more

Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics

Maryam Ahmadi, Christine J. Bryson, Edward A. Cloake, Katie Welch, Vasco Filipe, Stefan Romeijn, Andrea Hawe, Wim Jiskoot, Matthew P. Baker, Mark H. Fogg. Pharmaceutical Research, An Official Journal of the American Association of Pharmaceutical Scientists, ISSN 0724-8741, Pharm Res, DOI 10.1007/s11095-014-1541-x Abstract PURPOSE: Determine the effect of minute quantities of sub-visible aggregates on the in vitro immunogenicity of clinically […] Read more

Drug Discovery Tutorial: Detection and Reduction of Immunogenicity

Drug Discovery Tutorial: Detection and Reduction of Immunogenicity This article discusses how early removal of T-cell epitopes reduces risk of adverse immune responses in patients and how technologies such as Composite Human Antibodies can achieve this. Ji-won Choi. GEN; March 2015. Read more


Abzena and Baylor Scott & White Research Institute team up to form Denceptor Therapeutics to develop novel immunotherapies

Cambridge, UK and Dallas, US  – July 2016 – Abzena plc (AIM: ABZA, “Abzena” or the “Group”) and the Baylor Scott & White Research Institute announce the formation of a joint venture company, Denceptor Therapeutics Limited (“Denceptor”). Denceptor will develop Abzena inside immunotherapeutic products to treat cancer and autoimmune diseases using Baylor Scott & White Research […] Read more

We’re changing the way we brand our businesses

To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP, PolyTherics and TCRS we will be changing the names under which they trade to Abzena. From the 15 March 2016 all employees will be sending emails from an email address, and you will begin to see the […] Read more

Appointment of Campbell Bunce as Senior Vice President, Scientific Operations

Adds further immunology expertise to Executive Management Team Cambridge, UK – Abzena plc (AIM:ABZA, ‘Abzena’), a life sciences group providing services and technologies that enable the development and manufacture of biopharmaceutical products, has appointed Dr Campbell Bunce to the new role of Senior Vice President, Scientific Operations. Campbell will join Abzena’s Executive Management Team, reporting […] Read more

Interested in our services? Get In Touch